Gastrointestinal stromal tumors (GIST) are rare mesenchymal tumors and were among the first solid tumor types for which such a novel treatment (in this case imatinib) became available. The ...

Researchers from the University of Colorado Anschutz Medical Campus have identified a new feature indicative of the chance of recurrence of Gastrointestinal Stromal Tumors (GISTs).

DelveInsight’s “Gastrointestinal Stromal Tumor Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Gastrointestinal Stromal Tumor ...

More information: Feifei Xie et al, Genomic and transcriptomic landscape of human gastrointestinal stromal tumors, Nature Communications (2024). DOI: 10.1038/s41467-024-53821-1 Provided by BGI ...

GISTs are a rare type of cancer that develops in the digestive tract’s connective tissue, specifically from cells that help regulate muscle contractions. GISTs are primarily driven by genetic ...

Huntsman Cancer Institute’s Sarcoma Service has a specialist team that treats soft-tissue sarcomas that form in the abdomen. Here are some soft-tissue sarcomas of the abdomen: Gastrointestinal stromal ...

New York, USA, Oct. 19, 2022 (GLOBE NEWSWIRE) -- 24+ Key Companies Actively Working in the Gastrointestinal Stromal Tumor Pipeline Segment | DelveInsight DelveInsight’s 'Gastrointestinal Stromal ...

New York, USA, April 15, 2025 (GLOBE NEWSWIRE) -- Gastrointestinal Stromal Tumor Market to Grow Rapidly During the Study Period (2020–2034) Owing to the Launch of Emerging Therapies | DelveInsight ...

DUBLIN--(BUSINESS WIRE)--The "Gastrointestinal Stromal Tumors - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering. The "Gastrointestinal Stromal Tumors - ...

Cogent Biosciences is a biotechnology company focused on developing solutions for complex medical conditions, with a particular focus on Gastrointestinal Stromal Tumors. Bezuclastinib is a ...

The most common clinical presentation was abdominal discomfort, followed by GI bleeding ... non-gastric origin, larger tumor size, higher mitotic rate, higher risk grade, CD34 negative expression ...

A recent study offering a comprehensive view of the genome and transcriptome of gastrointestinal stromal tumors (GISTs) has introduced a new, multi-omics-based molecular classification of these ...